Search by
Industry
Department

Biologic vs. Non-biologic: Current FDA Thinking on IVDs

In the United States, in vitro diagnostic products are classified and reviewed under two separate FDA Centers, depending on whether the product is intended to be used to diagnose a condition, predict if a particular treatment will be effective or monitor the effect of a treatment, or if it is intended to be used in the testing of transfusable blood or cellular products.


In this audio conference we highlight the differences in the two product review processes between the Centers and provide insight into their expectations regarding information required in submissions and following product approval. Recent Guidance Documents issued by FDA are discussed.


This audio conference covers:


  • Which FDA Center has primary review responsibility for which IVD products
  • The importance of intended use, how it affects FDA classification and to which Center it will be assigned for review
  • The main concerns of each FDA Center in reviewing submissions for approval/clearance
  • The type of clinical data used in support of IVD submissions and the regulations surrounding collection of that data
  • Post-marketing requirements for change notification and product deviations


About the speakers:


Ann Quinlan-Smith is President of Alquest, Inc. She has worked in the medical industry for 25 years in technical disciplines as well as in the areas of clinical, regulatory and compliance. She has managed both personnel and projects in these areas, including US and International strategy development and implementation.


Ms. Quinlan-Smith has an established background as an instructor and trainer, through her frequent speaking engagements at local industry meetings and her past participation on the faculty of the Biomedical Program at Anoka Ramsey Community College. Ms. Quinlan-Smith has a B.S. in Medical Technology, a Masters degree in Business Administration (MBA), and has earned the Regulatory Affairs Certification (RAC) distinction from the Regulatory Affairs Professional Society (RAPS).


Pamela J. Vaughan is Senior Principal Consultant at Alquest, Inc. She has worked in the medical industry for over 30 years in quality assurance, quality control, manufacturing, and regulatory affairs. She has extensive experience in developing and maintaining GMP compliant quality systems to support manufacture of drugs, biologics, IVDs and medical devices.


Her background includes design, construction, validation, and start-up of biologics and drug manufacturing facilities; production of injectable grade products, and production of monoclonal antibodies for therapeutic use. She has several years of management and supervisory experience, has provided in-house and third party quality audits and training, and is experienced with preparing INDs, DMFs, BLAs and PMAs. She is a member of the American Society of Quality (ASQ), the Henrici Society of Microbiologists, and Regulatory Affairs Professional Society (RAPS). Ms. Vaughan has a B.A. in Biology/Microbiology, has earned Regulatory Affairs Certification (RAC) from RAPS, and is an ASQ Certified Quality Auditor (CQA).


Who should attend?


  • Clinical Research Managers
  • Regulatory Managers
  • Compliance Department Managers
  • Study Managers
  • Manufacturing Personnel


This audio conference is rated General Interest.

Speaker & Time

Ann Quinlan-Smith & Pamela J. Vaughan, Alquest, Inc.
Biologic vs. Non-biologic: Current FDA Thinking on IVDs
Title: President & Senior Principal Consultant
Duration: 60 minutes
Discount: Buy 2 items, get 25% off your order using coupon code FX25%OFF
Event Type: Previously recorded on 2008-02-28
Item #: ac20080527
28 Feb 2008 
Registration Price:
$249.00

Order Info

Select Order Type:  
Include Transcript With Order?:  
Quantity
More
Less
 
 
Bookmark and Share reviews

Reviews

Average Rating: (based on 5 reviews)

Showing 1 to 4 of 5 Reviews:

by H.Y.
Regulatory Affairs Director
More IVD-related or with an IVD focus.
by I.P.
Regulatory Director
One element that was not covered in this discussion of biologic regulatory requirements was INDs. It would have been helpful to have this in the presentation. I realize that there were time constraints. That is why most audio conferences are 1.5 hours.
by C.C.
Technical Information Coordinator
Make slides less busy. More slides with less text per slide is preferable.
by Julie Black
Biologic vs. Non-biologic: Current FDA Thinking on IVDs
This audio conference gave a very good general overview of the 510(k) submission process and helped a lot of my non-IVD involved colleagues to understand the ins and outs of getting an IVD to market and what happens afterward.
12
Rate this item
Similar Events
How to Respond to FDA 483s and Warning Letters
Alan Schwartz, mdi Consultants, Inc.
More about How to Respond to FDA 483s and Warning Letters


Good Reprint Practices: What the FDA Says Now
Robert J. Klepinski, Fredrikson & Byron
More about Good Reprint Practices: What the FDA Says Now


More about Indications: The Next Battleground in FDA Advertising Enforcement

 
Recently Viewed
Setting Up and Managing a European Distribution Network
Michael van der Woude, EDM Services
More about Setting Up and Managing a European Distribution Network


Best Practices for Back Translation as a QA Tool
Hilary Davies, ForeignExchange Translations
More about Best Practices for Back Translation as a QA Tool


The Pre-IND Program: 12 Steps to a Successful IND Filing
Dr. Larry Hofmann, LMH Associates, Inc.
More about The Pre-IND Program: 12 Steps to a Successful IND Filing


The New Rules for CME Sponsors and Providers
Maria D. Buckley, Nutter McClennen & Fish LLP
More about The New Rules for CME Sponsors and Providers


Best Practices for Creating & Translating Global Content
Steve Billings & Bill Rabkin, Idiom Technologies
More about Best Practices for Creating & Translating Global Content

© Copyright 2010
ForeignExchange Translations.
All rights reserved.

Home  |   FAQ  |   Blog  |   Translation Services  |   Search  |   Privacy Policy  |   Terms of Use  |   Contact Us